Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 4:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 28 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Transdermal placebo gel Clear all
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Testosterone Gel Applied to Women With Pituitary Gland Problems

NCT00144391
View directory record Official record
Conditions
Panhypopituitarism
Interventions
Transdermal Testosterone gel
Drug
Lead sponsor
Charles Drew University of Medicine and Science
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness

NCT04184115
View directory record Official record
Conditions
Motion Sickness
Interventions
DPI-386 Nasal Gel, Placebos
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT01235754
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
transdermal testosterone gel 1%, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 66 Years · Female only
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
98
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

NCT00952731
View directory record Official record
Conditions
Ductal Breast Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Interventions
oral placebo, afimoxifene, tamoxifen citrate, placebo gel
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 20, 2015 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Clinical Study Of caNNabidiol in childrEn and adolesCenTs With Fragile X (CONNECT-FX)

NCT03614663
View directory record Official record
Conditions
Fragile X Syndrome
Interventions
ZYN002 - Cannabidiol Transdermal Gel, Placebo Transdermal Gel
Drug · Other
Lead sponsor
Zynerba Pharmaceuticals, Inc.
Industry
Eligibility
3 Years to 17 Years
Enrollment
212 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
17
States / cities
Phoenix, Arizona • Sacramento, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2022 · Synced Sep 16, 2026, 4:06 PM EDT
Terminated Not applicable Interventional

Comparison of the Efficacy of Topical Ibuprofen to Oral Ibuprofen in Adolescent Athletes

NCT00567528
View directory record Official record
Conditions
Soft Tissue Injury
Interventions
ibuprofen
Drug
Lead sponsor
Akron Children's Hospital
Other
Eligibility
12 Years to 19 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Akron, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 13, 2015 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes

NCT02513940
View directory record Official record
Conditions
Long QT Syndrome
Interventions
Testosterone, Progesterone, Placebo, Ibutilide
Drug
Lead sponsor
Indiana University
Other
Eligibility
65 Years and older · Male only
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 27, 2019 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for the Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00613002
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
597 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
60
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 56 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Sep 16, 2026, 4:06 PM EDT
Recruiting Phase 4 Interventional

Menopausal HT for Women Living With HIV (HoT)

NCT06856174
View directory record Official record
Conditions
HIV Infection, Menopause
Interventions
Transdermal estradiol gel, Micronized Progesterone, Placebo for estradiol gel, Placebo for micronized progesterone
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
40 Years to 60 Years · Female only
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cardiovascular Outcomes of Low Testosterone

NCT02758431
View directory record Official record
Conditions
Hypogonadism
Interventions
Acyline, Placebo Gel, Placebo Tablet, Testosterone Gel, Arimidex
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
232 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2023
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Sep 16, 2026, 4:06 PM EDT
Terminated Phase 2 Interventional Results available

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel

NCT02349386
View directory record Official record
Conditions
Cancer of the Prostate
Interventions
BHR-200 (0.36% transdermal 17β-estradiol gel), Placebo
Drug
Lead sponsor
BHR Pharma, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
12
States / cities
Tucson, Arizona • Aventura, Florida • Daytona Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2022 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

NCT00163566
View directory record Official record
Conditions
Hypogonadism, Late Onset Hypogonadism, Low Testosterone
Interventions
Dihydrotestosterone (0.7%) in hydroalcoholic gel
Drug
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
55 Years to 80 Years · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Phoenix, Arizona • Torrance, California • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 2 Interventional Results available

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

NCT02993159
View directory record Official record
Conditions
Ductal Breast Carcinoma In Situ, Estrogen Receptor Positive
Interventions
Afimoxifene, Laboratory Biomarker Analysis, Placebo, Tamoxifen Citrate
Drug · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
6
States / cities
Chicago, Illinois • Edgewood, Kentucky • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 16, 2026, 4:06 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Study of the Safety and Efficacy of DPI-386 Nasal Gel on Ocean-Going Vessels

NCT03920644
View directory record Official record
Conditions
Prevention of Nausea Associated With Motion Sickness, Treatment of Nausea Associated With Motion Sickness
Interventions
Scopolamine Transdermal Patch [Transderm Scop], Scopolamine, Placebo Patch, Placebo Gel
Drug
Lead sponsor
Naval Aeromedical Research Unit, Dayton
Federal
Eligibility
18 Years to 59 Years
Enrollment
320 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 18, 2019 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening

NCT04675788
View directory record Official record
Conditions
Long QT Syndrome, Abnormalities, Drug-Induced
Interventions
Progesterone, Ibutilide, Testosterone, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
50 Years to 99 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 3 Interventional Results available

Study of Topically Administered Oxybutynin Gel in Patients With Urge Incontinence

NCT00909181
View directory record Official record
Conditions
Urge Urinary Incontinence, Urinary Frequency
Interventions
Oxybutynin, Placebo
Drug
Lead sponsor
Antares Pharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
55
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Laguna Hills, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 16, 2026, 4:06 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Transdermal Testosterone Gel for Female Sexual Interest and Arousal Disorder in Peri- and Post Menopause

NCT07408440
View directory record Official record
Conditions
Menopause, Sexual Dysfunction, Libido Disorder, Testosterone Deficiency
Interventions
Transdermal testosterone gel, Transdermal placebo gel
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
40 Years to 65 Years · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 2 Interventional

Iontophoretic Application of Acyclovir Gel to Treat Cold Sores

NCT00469300
View directory record Official record
Conditions
Herpes Labialis
Interventions
Iontophoretic delivery of acyclovir
Drug
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Rosa, California • Pinellas Park, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2008 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

T-IR- Study to Understand the Effects of Testosterone and Estrogen on the Body's Response to the Hormone Insulin

NCT01686828
View directory record Official record
Conditions
Insulin Resistance, Type 2 Diabetes Mellitus, Obesity, Androgen Deficiency, Metabolic Disease
Interventions
Acyline, Testosterone 1.62% gel, Letrozole, Placebo gel (for Testosterone 1.62% gel), Placebo pill (for Letrozole)
Drug
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 7, 2018 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

PROS-1-Male Hormonal Contraceptive Regimens on Prostate Tissue

NCT00490555
View directory record Official record
Conditions
Healthy
Interventions
Testosterone gel, Dutasteride, Depo-Medroxyprogesterone (DMPA), Placebo Testosterone gel, Placebo dutasteride, Placebo DMPA
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
25 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 14, 2013 · Synced Sep 16, 2026, 4:06 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Nasal Gel Under Military Operational Conditions for the Prevention of Nausea Associated With Motion Sickness

NCT04272255
View directory record Official record
Conditions
Motion Sickness
Interventions
scopolamine HBr, Transdermal Scopolamine
Drug
Lead sponsor
Repurposed Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Dayton, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 16, 2020 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Modulation of GABA-A Receptors in Parkinson Disease-Transdermal Flumazenil Arm

NCT03440112
View directory record Official record
Conditions
Parkinson Disease
Interventions
Clarithromycin (Not used as of 4/2020), Placebo (Not used as of 4/2020), Transdermal flumazenil (Added 4/2020), Placebo (Added 4/2020)
Drug
Lead sponsor
Nicolaas Bohnen, MD, PhD
Other
Eligibility
50 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 9, 2023 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 4 Interventional Results available

AndroGel in Men With Major Depression and Incomplete Response to Antidepressant Treatment

NCT00304746
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Testosterone gel, Placebo
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
30 Years to 65 Years · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 23, 2010 · Synced Sep 16, 2026, 4:06 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women

NCT00612742
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
50 Years and older · Female only
Enrollment
3,656 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
141
States / cities
Birmingham, Alabama • Hoover, Alabama • Huntsville, Alabama + 116 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Sep 16, 2026, 4:06 PM EDT